Abstract
The development of novel interventions against a disease entails optimising their specifications to achieve desired health goals such as disease reduction. As testing is limited early in development, it is difficult to predefine these optimal specifications, prioritize or continue investment in candidate interventions. Mathematical models of disease can provide quantitative evidence as they can simulate deployment and predict impact of a new intervention considering deployment, health-system, population and disease characteristics. However, due to large uncertainty early in development, as well as model complexity, testing all possible combinations of interventions and deployments becomes infeasible. As a result, mathematical models have been only marginally used during intervention development to date. Here, we present a new approach where machine learning enables the use of detailed disease models to identify optimal properties of candidate interventions to reach a desired health goal and guide development. We demonstrate the power of our approach by application to five novel malaria interventions under development. For various targeted reductions of malaria prevalence, we quantify and rank intervention characteristics which are key determinants of health impact. Furthermore, we identify minimal requirements and tradeoffs between operational factors, intervention efficacy and duration to achieve different levels of impact and show how these vary across disease transmission settings. When single interventions cannot achieve significant impact, our method allows finding optimal combinations of interventions fulfilling the desired health goals. By enabling efficient use of disease models, our approach supports decision-making and resource investment in the development of new interventions for infectious diseases.
Significance Statement During development of novel disease interventions (e.g. vaccines), a target product profile (TPP) document defines intervention characteristics required to meet health goals. As clinical trials are limited early in development, mathematical models simulating disease dynamics can help define TPPs. However, testing all combinations of intervention, delivery and environment characteristics is infeasible and so complex mathematical models have not been used until now. We introduce a new approach to define TPPs, combining models of disease with machine learning. We examined several novel malaria interventions, identifying key characteristics, minimum efficacy and duration of effect that ensure significant reductions in malaria prevalence. This approach therefore enabled mathematical models of disease to support intervention development, by identifying intervention requirements that ensure public health impact.
One Sentence Summary Defining quantitative profiles of novel disease interventions by combining machine learning with mathematical models of disease transmission
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Bill and Melinda Gates Foundation (OPP1170505 to MAP) and the Swiss National Science Foundation (PP00P3_170702 to MAP)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.